Progression of spinocerebellar ataxia type 2. What do we need to know?

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(11): 765-766
DOI: 10.1590/0004-282X20170166

Editorial

Progressão da ataxia espinocerebelar tipo 2. O que precisamos saber?

Henrique Ballalai Ferraz

¹Universidade Federal de São Paulo, Escola Paulista de Medicina, Univerdade de Distúrbios do Movimento, São Paulo SP Brasil

Univerdade de Distúrbios do Movimento, Brasil

References
1 Antenora A, Rinaldi C, Roca A, Pane C, Lieto M, Saccà Fet al. The multiple faces of spinocerebellar ataxia type 2. Ann Clin Transl Neurol. 2017;4(9):687-95. https://doi.org/10.1002/acn3.437
2 Velázquez-Pérez LC, Rodríguez-Labrada R, Fernandez-Ruiz J. Spinocerebellar ataxia type 2: clinicogenetic aspects, mechanistic insights, and management approaches. Front Neurol. 2017;8:472. https://doi.org/10.3389/fneur.2017.00472
3 Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544(7650):362-6. https://doi.org/10.1038/nature22044
4 Amarante TRP, Takeda SYM, Teive HAG, Zonta MB. Impact of disease duration on functional status of patients with spinocerebellar ataxia type 2. Arq Neuropsiquiatr. 2017;75(1 1):773-77. https://doi.org/10.1590/0004-282X20170146
5 Sarro L, Nanetti L, Castaldi A, Mariotti C. Monitoring disease progression in spinocerebellar ataxias: implications for treatment and clinical research. Expert Rev Neurother. 2017;17(9):919-31. https://doi.org/10.1080/14737175.2017.1364628